![](https://www.biopharmadive.com/imgproxy/aFO49QT1-ytbqrjsghNN87eKIlQQL6Xv-4smpw2yyUw/g:nowe:909:0/c:6097:3444/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODM5MjE3OTMuanBn.webp)
Vir retreats from infectious disease; Vertex shelves AATD drugs
Today, a brief rundown of news from Vir Biotechnology and Vertex Pharmaceuticals, as well as updates from Neurocrine Biosciences, Alnylam Pharmaceuticals and venBio that you may have missed. Vir Biotechnology is cutting one-quarter of its workforce in a …